.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,078,866

« Back to Dashboard

Details for Patent: 9,078,866

Title:Method for treating hyperglycemia with GLP-1
Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with Type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
Inventor(s): Costello; Donald (Bridgewater, NJ), Richardson; Peter (Ringoes, NJ), Baughman; Robert A. (Ridgefield, CT), Marino; Mark T. (Long Valley, NJ)
Assignee: MannKind Corporation (Valencia, CA)
Filing Date:Jan 08, 2010
Application Number:13/257,284
Claims:1. A method for treating hyperglycemia, comprising the step of administering to a human subject having a fasting blood glucose concentration greater than about 7 mmol/L an inhalable dry powder formulation comprising microparticles comprising a therapeutically effective amount of a glucagon like peptide-1 (GLP-1) molecule and a diketopiperazine, wherein the GLP-1 molecule is a native GLP-1, a GLP-1 metabolite, a GLP-1 analog, a long acting GLP-1 analog, a GLP-1 mimetic, a GLP-1 peptide analog, a biosynthetic GLP-1 analog, or a combination thereof, wherein said GLP-1 has at least one biological activity of native GLP-1, and wherein said GLP-1 comprises GLP-1 in an amount from about 0.5 mg to about 3 mg of GLP-1 in the formulation and the formulation does not comprise a dipeptidyl-peptidase-IV (DPP-IV) inhibitor, and wherein the diketopiperazine is 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is selected from the group consisting of succinyl, glutaryl, maleyl, and fumaryl; or a pharmaceutically acceptable salt thereof, and further wherein peak blood GLP-1 concentration is reached within about 20 minutes after administration.

2. The method of claim 1, wherein the patient is a mammal having Type 2 diabetes mellitus.

3. The method of claim 1 wherein the human subject has a fasting blood glucose concentration greater than about 9 mmol/L.

4. The method of claim 1 wherein X is fumaryl.

5. The method of claim 1, wherein the inhalable formulation is administered to said human subject prandially.

6. The method of claim 1 wherein the composition is administered pulmonarily.

7. A method for reducing glucose levels in a Type 2 diabetic patient, the method comprising the step of administering to said patient in need of treatment a dry powder inhalable formulation for pulmonary administration comprising microparticles comprising a therapeutically effective amount of a GLP-1, and a diketopiperazine or pharmaceutically acceptable salt thereof, wherein the Type 2 diabetic patient has a fasting blood glucose concentration greater than 8 mmol/L, wherein said GLP-1 comprises GLP-1 in an amount from about 0.5 mg to about 3 mg of GLP-1 in the formulation and the formulation does not comprise a DPP-IV inhibitor, and wherein the diketopiperazine is 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is selected from the group consisting of succinyl, glutaryl, maleyl, and fumaryl, and further wherein peak blood GLP-1 concentration is reached within about 20 minutes after administration.

8. The method of claim 7, wherein the glucose levels are reduced by about 0.1 mmol/L to about 3 mmol/L for a period of approximately four hours after administration of said inhalable formulation to said Type 2 diabetic patient.

9. The method of claim 7, wherein the inhalable formulation is administered to said Type 2 diabetic patient prandially, preprandially, post-prandially or in a fasting state.

10. The method of claim 9, wherein the inhalable formulation is administered to said Type 2 diabetic patient prandially.

11. The method of claim 7 wherein the patient has a fasting blood glucose concentration greater than about 9 mmol/L.

12. The method of claim 7 wherein X is fumaryl.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc